Entelos Acquires Option to Phase I Compound from Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

FOSTER CITY, Calif., Jan. 11, 2007 - Entelos, Inc. (LSE: ENTL), a leading life sciences company building predictive computer models of human physiology and "virtual patients" for drug discovery and development, announced today that it has entered into an agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C., (J&JPRD), to acquire an option to an exclusive worldwide license to develop selective progesterone-receptor modulators for a range of indications. The deal reinforces Entelos' stated strategy to leverage its industry-leading, revenue-generating biosimulation services to enable proprietary drug development. Entelos is providing biosimulation services to J&JPRD, compensated in part through the grant of this option, and will develop a new PhysioLab(r) platform to support its internal development of the compound.

"The medical need for better, safer, and more targeted therapies is greater than ever, as the number of age-related diseases continues growing," stated James Karis, president and CEO of Entelos. "Acquiring the option to develop selective progesterone receptor modulators reflects our strategy to leverage our predictive disease simulation systems into drug ownership rights. We believe our technology and approach can make a significant impact in the drug development process by reducing the complexity and risks, and ultimately revolutionizing the way therapies are selected, developed, and customized to help patients."

About Entelos

Entelos, Inc. (www.entelos.com <http://www.entelos.com/> ) is a US-based life sciences company building predictive in silico disease models and using "virtual patients" to revolutionize the way medicines are discovered, developed, and utilized. The Company's predictive biosimulation computer models, known as PhysioLab(r) systems, are used to validate novel drug targets, select and develop compounds, assess safety, optimize clinical trials and combination therapies, reprofile drugs, evaluate in-licensing candidates, and better position existing products in competitive markets. In addition to internal programs, Entelos partners with global pharmaceutical and biotechnology companies and currently provides scientific expertise and models in such areas as cardiovascular disease, asthma, obesity, diabetes and rheumatoid arthritis, and complex physiological processes such as hematopoiesis (anemia), cholesterol metabolism, and skin sensitization.

Enquiries

Entelos, Inc.

Jill Fujisaki, Vice President, Investor Relations

Tel: +1 650 572 5430

fujisaki@entelos.com

Brunswick Group

Justine McIlroy / Alex Tweed / Jon Coles

Tel: +44 207404 5959

If you would prefer not to receive press releases from Entelos, click here PR@entelos.com> and enter 'Remove' in the subject line.

Posted: January 2007


View comments

Hide
(web3)